A double‐blind placebo‐controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation

Würtzen, Peter Adler; Lund, G.; Lund, Kaare; Arvidsson, Monica; Rak, S.; Ipsen, Hans Henrik

doi:10.1111/j.1365-2222.2008.03020.x

Cited by 101 publications

(123 citation statements)

References 53 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Confirming previous studies, IgE binding to EBV-B cells was observed for BPA patients (10,21). Also for PA patients, binding of complexes to these cells was observed, whereas for CMA patients, binding was less pronounced.…”

Section: Discussionsupporting

confidence: 76%

IgG Antibodies in Food Allergy Influence Allergen–Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors

Meulenbroek

Jong

Jäger

et al. 2013

The Journal of Immunology

View full text Add to dashboard Cite

Allergen–IgE complexes are more efficiently internalized and presented by B cells than allergens alone. It has been suggested that IgG Abs induced by immunotherapy inhibit these processes. Food-allergic patients have high allergen-specific IgG levels. However, the role of these Abs in complex formation and binding to B cells is unknown. To investigate this, we incubated sera of peanut- or cow’s milk–allergic patients with their major allergens to form complexes and added them to EBV-transformed or peripheral blood B cells (PBBCs). Samples of birch pollen-allergic patients were used as control. Complex binding to B cells in presence or absence of blocking Abs to CD23, CD32, complement receptor 1 (CR1, CD35), and/or CR2 (CD21) was determined by flow cytometry. Furthermore, intact and IgG-depleted sera were compared. These experiments showed that allergen–Ab complexes formed in birch pollen, as well as food allergy, contained IgE, IgG1, and IgG4 Abs and bound to B cells. Binding of these complexes to EBV-transformed B cells was completely mediated by CD23, whereas binding to PBBCs was dependent on both CD23 and CR2. This reflected differential receptor expression. Upon IgG depletion, allergen–Ab complexes bound to PBBCs exclusively via CD23. These data indicated that IgG Abs are involved in complex formation. The presence of IgG in allergen–IgE complexes results in binding to B cells via CR2 in addition to CD23. The binding to both CR2 and CD23 may affect Ag processing and presentation, and (may) thereby influence the allergic response.

show abstract

Section: Discussionsupporting

confidence: 76%

IgG Antibodies in Food Allergy Influence Allergen–Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors

Meulenbroek

Jong

Jäger

et al. 2013

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated in several studies that serum obtained from subjects receiving birch pollen immunotherapy inhibits IgE-facilitated presentation of allergen by B-cells to an allergen-specific T-cell clone [Van Neerven et al 1999;Wurtzen et al 2008]. Furthermore, serum obtained from patients that received grass pollen immunotherapy could inhibit IgE-facilitated allergen presentation to a grass-specific T-cell clone [Wachholz et al 2003].…”

Section: Humoral Changesmentioning

confidence: 99%

“…After the initial induction of sIgG4 the levels decrease after discontinuation of treatment, although are still elevated compared with baseline levels. It is thought that IgG4 competes with allergen-binding to the IgE on the Fcε receptors of mast cells and basophils, and thus acts as a blocking antibody that prevents the activation and degranulation of effector cells [Van Neerven et al 1999;Wurtzen et al 2008]. In addition, some other features of IgG4 suggest that it could have an anti-inflammatory role.…”

Section: Humoral Changesmentioning

confidence: 99%

Applications and mechanisms of immunotherapy in allergic rhinitis and asthma

Kappen

Durham

Veen

et al. 2016

Ther Adv Respir Dis

View full text Add to dashboard Cite

Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such as mast cells, eosinophils and basophils in target organs. Furthermore, AIT down-regulates type 2 innate lymphoid cells and allergen-specific type 2 T-helper (Th2) cells. The immunologic tolerant state following AIT is associated with the induction of distinct phenotypes of regulatory T-cells (T-regs) including interleukin (IL)-10-, IL-35-and transforming growth factor (TGF)-β-producing T-regs and FoxP3 + T-regs. B-cell responses, including the induction of IL-10 + regulatory B-cells (B-regs) and the production of IgG4-associated blocking antibodies are also induced following successful AIT. These events are associated with the suppression of antigen-specific Th2 responses and delayed immune deviation in favour of Th1 type responses. Insight into the mechanisms of AIT has allowed identification of novel biomarkers with potential to predict the clinical response to AIT and also novel therapeutic strategies for more effective and safer AIT.

show abstract

“…For olive pollen, preseason SCIT has shown to produce significant improvement both in nasal and bronchial symptoms, and a decrease in the consumption of rescue medication [95]. For birch pollen, SCIT induced immunological changes in T cell populations and Ig subtypes [96,97] and a reduction of symptom score for rhinoconjunctivitis and asthma and total medication score [98]. Several randomized trials have evaluated the efficacy of SCIT for grass pollen allergy in patients with chest symptoms.…”

Section: Subcutaneous Immunotherapymentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

A double‐blind placebo‐controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation

Cited by 101 publications

References 53 publications

IgG Antibodies in Food Allergy Influence Allergen–Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors

IgG Antibodies in Food Allergy Influence Allergen–Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors

Applications and mechanisms of immunotherapy in allergic rhinitis and asthma

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Contact Info

Product

Resources

About